Arrieta Bolanos, ER; Madrigal, JA; Shaw, BE; Marsh, SGE; Salazar-Sánchez, L; (2012) The frequency of HLA-B*57:01 and the risk of Abacavir hypersensitivity reactions in the Costa Rica Central Valley Population. Presented at: The Joint 16th International HLA and Immunogenetics Conference/26th European Immunogenetics and Histocompatibility Conference/23rd British Society of Histocompatibilty and Immunogenetics Conference, Liverpool, UK.

Preview

PDF 1346810_EA B5701 BSHI Poste JR Edit.pdf Available under License : See the attached licence file. Download (3MB)

Abstract

HLA-B*57:01 is a pharmacogenetic marker for abacavir hypersensitivity among HIV+ individuals. The utility and cost-effectiveness of the typing of this allele as a prospective marker has been confirmed to decrease or abolish abacavir hypersensitivity reactions in these patients. However, as for other HLA alleles, there is widespread variation in its frequency across populations. Thus, characterisation of the frequency of this marker in a given population is the first step towards the evaluation of the feasibility and need of pharmacogenetic screening for this drug. The Costa Rica Central Valley Population (CCVP) is the major population in this country. The frequency of HLA-B*57:01 in this population has not been described yet. Consequently, in an exploratory study, we set out to determine the frequency of this allele in a sample of unrelated healthy blood donors. We genotyped 153 samples from CCVP inhabitants. The samples were typed to intermediate resolution by SSO or SSP methods, and samples that were HLA-B*57-positve were further typed by sequence- based typing in order to define the alleles to four-digit resolution. An HLA-B*57:01 carrier frequency of 5.23% (allele frequency of 2.61%) was determined in this sample. This frequency is relatively high in comparison to reports from other populations in Latin America. These results suggest that there is a considerable frequency of HLA-B*57:01 in the CCVP and that pharmacogenetic testing for HIV+ patients who are going to receive abacavir-based treatment schemes is likely to benefit the security of this therapy. According to WHO data, we hypothesize that some 200,000 persons in this country would be susceptible to abacavir- induced hypersensitivity, and that some 15,000 HIV+ people living in Costa Rica could benefit from prospective HLA-B*57:01 genotyping.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item